Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $18 price target.
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...
CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative med...
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.
